Summarized by Masters of Longevity from PR Newswire.
Preview of a global oncology meeting highlighting 64 clinical and pipeline updates across multiple cancer indications and modalities from a single developer.
Key Takeaways
- Two internally developed ADCs were selected for Proffered Paper presentations at the congress.
- A phase 3 trial comparing a HER3-targeted ADC with platinum chemotherapy reported positive results prompting an NMPA marketing review.
- A KRAS G12D inhibitor combination and a PD-1 plus radiotherapy regimen are among other clinical programs presented.
